

Headlines
Personalised mRNA cancer vaccine and Keytruda combination reduces melanoma recurrence risk in clinical trial
LONDON — A new personalised cancer vaccine combined with the established immunotherapy drug Keytruda has cut the risk of patients dying or their skin cancer returning by 42% in a major clinical trial. The trial, which involved 1,137 adults, found that the drug combination also reduced the risk of melanoma spreading by 38% over two











